WHC is still in active development. Read this to understand our approach.
depiction of KWGRBVOPPLSCSI-UHFFFAOYSA-N.svg
tripsit

pseudoephedrine

Verificar en tripsit

tripsit

ephedrine

Verificar en tripsit

psychonaut

Ephedrine

Verificar en psychonaut

psychonaut

Pseudoephedrine

Verificar en psychonaut

isomerdesign

Phenylpropanolmethyl...

Verificar en isomerdesign

isomerdesign

(1R,2S)-2-(Methylami...

Verificar en isomerdesign

isomerdesign

(1S,2S)-2-(Methylami...

Verificar en isomerdesign

pubchem

Pseudoephedrine

Verificar en pubchem

pubchem

Ephedrine

Verificar en pubchem

druglab

Éphédrine

Verificar en druglab

drugmap

Ephedrine

Verificar en drugmap

drugmap

Ephedrine

Verificar en drugmap

wiki

Ephedrine

Verificar en wiki

wiki

Pseudoephedrine

Verificar en wiki

Data

InChI: InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3

Sinónimos: (R-(R*,S*))-.ALPHA.-(1-(METHYLAMINO)ETHYL)BENZENEMETHANOL [WHO-IP], Pseudoephedrine d-form,SR-01000075166-1,Pseudoephedrine, L-(+)-,D00124,PSEUDOEPHEDRINE HYDROCHLORIDE IMPURITY A [EP IMPURITY],EPHEDRINE [USP MONOGRAPH],Ephedrine, L-(-)-,trans-Ephedrine,1-2-Methylamino-1-phenylpropanol,1-Phenyl-2-methylaminopropanol,Ephedrine l-form, Ephedremal,(1S,2S)-2-(Methylamino)-1-phenylpropan-1-ol, L-(-)-Ephedrine,Ephedrine (TN), Pseudoefedrina [INN-Spanish],SBI-0051362.P003,Manadrin, (1S,2R)-Ephedrine,(1R*,2S*)-2-methylamino-1-phenyl-1-propanol,HY-B1195,Pseudoephedrine Ephedrine,Pseudoephedrine d-form,Pseudoefedrina [INN-Spanish],NSC-170951,Ephedral, Pseudoephedrine [INN:BAN],alpha-Hydroxy-beta-methyl amine propylbenzene,1-Phenyl-1-hydroxy-2-methylaminopropane,Emerphed (ephedrine sulfate injection),Ephedrine (USP), Sudafed (TN),CHEMBL1590,(-)-Ephedrine hemisulfate,PSEUDOEPHEDRINE [VANDF],Sudafed,DTXSID0022985, Triaminic Infant Oral Decongestant Drops,Sanedrine,EPHEDRINUM, ANHYDROUS [WHO-IP LATIN],BSPBio_003261,UNII-GN83C131XS,Besan,(1R,2S)-2-Methylamino-1-phenylpropan-1-ol,1-Hydroxy-2-methylamino-1-phenylpropane,(1S,2S)-(+)-Pseudoephedrine,Efedrin,Lopac-E-3250,(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol,Ephedrosan, Kratedyn,l-Erythro-2-(methylamino)-1-phenylpropan-1-ol,Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (R-(R*,S*))-,d-Pseudoephedrine base,NCGC00162174-01,pseudophedrine sulphate,racephedrine,Ephedrinum, anhydrous,alpha-(1-(Methylamino)ethyl)benzenemethanol,EC 202-018-6,Nasol,Ephedrotal,(1S,2S)-2-methylamino-1-phenylpropan-1-ol,NCI-C55652,Q263958,Pseudoephedrine [INN:BAN],Acunaso (TN),DTXSID0023537,AKOS016011257,90-82-4, Alpha-(1-(Methylamino)ethyl)benzyl alcohol,CHEMBL211456, I-Sedrin,(1S,2S)-Ephedrine,(1R,2S)-(-)-2-Methylamino-1-phenyl-1-propanol,(+)-threo-Ephedrine,AKOS025401512,Isoephedrine,(1S,2S)-Pseudoephedrine, 1-EPHEDRINE,Spectrum_000878,Ephedrol,alpha-(1-(Methylamino)ethyl)benzyl alcohol,DB00852, Lexofedrin, Pseudoephedrinum [INN-Latin],Psi-ephedrin,(I)-Ephedrin,UNII-7CUC9DDI9F,EPHEDRINE [MART.],C02765,(+)-psi-Ephedrine,PSEUDOEPHEDRINE [MI],Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-,EC 206-080-5,EPHEDRINE [VANDF], Triaminic AM Decongestant Formula, L-Ephedrine,(1S,2S)-(+)-Pseudoephedrine, 98%,PDSP2_001327,KBioGR_001763,Phenylpropanolmethylamine, (1S,2S)-Pseudoephedrine,KBio2_006494,Neodurasina,ZINC20259,Lexofedrin, Manadrin,KBio2_001358,299E423,2-(Methylamino)-1-phenyl-1-propanol,Pseudoephedrine, (+)-,NSC 8971,Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaR)-,d-psi-2-Methylamino-1-phenyl-1-propanol,L(+)-psi-Ephedrine,Spectrum3_001771,CS-4802,NCGC00162174-02,Pseudoephedrinum [INN-Latin],KBio3_002762,EPHEDRINE [MI],(1S,2S)-2-(Methylamino)-1-phenyl-1-propanol,SCHEMBL4368,(1R,2S)-(-)-Ephedrine, 98%,(-)-(1R,2S)-Ephedrine,Pseudoephedrine (D),PSEUDOEPHEDRINE [WHO-DD], D-Ephedrine,Acunaso,299-42-3, Mandrin, Pseudoephedrine (INN),C01575,HSDB 3072,(1S,2S)-2-Methylamino-1-phenylpropan-1-ol,Pseudoefedrina, (+)-(1S,2S)-Pseudoephedrine,AI3-02761,psi-Ephedrine, (+)-, Ephedrol,(+) threo-2-(methylamino)-1-phenyl-1-propanol,(1R,2S)-2-(methylamino)-1-phenyl-propan-1-ol, (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol,(1R,2S)-2-Methylamino-1-phenyl-1-propanol,Spectrum5_000650,EINECS 202-018-6,Mandrin,2-Methylamino-1-phenyl-1-propanol,d-psi-Ephedrine, CPDD 0049,Norephedrine, N-methyl-,(1s, 2s)-(+)-pseudoephedrine,Q219626,KBio2_003926,EPHEDRINE, ANHYDROUS [WHO-IP],Pseudoephedrine,NSC-8971,Ephedrin, Sudafed Decongestant 12 Hour,Fedrin,EPHEDRINE [HSDB],Ephedrine, anhydrous,Kratedyn,1(-)ephedrine, Nasol, (1S,2S)-Pseudoephedrine, polymer-bound,NCGC00015408-01, Ephedrital,Ephedremal,NCI60_002955, Ephedrin,(.ALPHA.S)-.ALPHA.-((1R)-1-(METHYLAMINO)ETHYL)BENZENEMETHANOL,KBio1_000451, 1-Sedrin,Spectrum2_001303,Biophedrin,Vencipon,Psi-ephedrine,Lopac0_000501,(1S,2S)-2-(methylamino)-1-phenyl-propan-1-ol, Vencipon,(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol,Ephedrital,J-500280, Dimetapp Decongestant Pediatric Drops,SCHEMBL4785,ephedrine-(racemic),NINDS_000451,(+) pseudoephedrine, Sanedrine,AB00375843_06, Efedrin,EINECS 206-080-5,1-Sedrin,d-Isoephedrine, Ephoxamin,(1s, 2s) pseudoephedrine,EPHEDRINE [EP MONOGRAPH],Spectrum4_001162,PDSP2_001330, Ephedrine (USP), Ephedrine l-form,l-alpha-(1-Methylaminoethyl)benzyl alcohol,d-Pseudoephedrine, (L)-EPHEDRINE,SPBio_001365,CHEBI:15407,Ephendronal,Ephoxamin,GN83C131XS,Benzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, (.alpha.S)-, (1R,2R)-Ephedrine, Ephendronal,Zephrol,KBioSS_001358,(R,S)-2-(Methylamino)-1-phenylpropan-1-ol,(1R,2S)-(-)-2-(N-methylamino)-1-phenylpropan-1-ol,L(-)-Ephedrine, Dimetapp Decongestant,BENZENEMETHANOL, .ALPHA.-((1S)-1-(METHYLAMINO)ETHYL)-, (.ALPHA.S)-,alpha-[1-(Methylamino)ethyl]-benzenemethanol, L-(+)-Ephedrine, L(-)-Ephedrine, Sudafed Decongestant Extra Strength,D08449,Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (-)-,(-)-alpha-(1-Methylaminoethyl)benzyl alcohol,(+)-Pseudoephedrine,PSEUDOEPHEDRINE,(+)-(1S,2S)-Pseudoephedrine, Ephedrotal, Ephedrine [USAN:BAN], (+)-Ephedrin,alpha-Hydroxy-beta-methylaminopropylbenzene,EPHEDRINE [WHO-DD],DEA Code 8113, Ephedrosan, Fedrin,ZINC74836,Xenadrine, Eciphin,CHEBI:51209,IDI1_000451, Efidac 24 PseudoephedrineHcl,(L)-EPHEDRINE,1-(S),2-(R)-ERYTHRO-(+)-EPHEDRINE,NCGC00178180-01,Neodurasina (TN),I-Sedrin,Pseudoephedrinum, Ephedrine (TN), D-psi-2-Methylamino-1-phenyl-1-propanol, Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-(9CI),BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (S-(R*,R*))-,Isoephedrine, d-,NSC 170951,(-)-Ephedrine,NSC170951,Pseudoephedrine polistirex,(1R,2S)-(-)-alpha-(1-Methylaminoethyl)benzenemethanol,Balminil Decongestant Syrup,064P256,BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (R-(R*,S*))-,Benzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, (.alpha.R)-, Ephedsol, Racephedrine,(1r, 2s)-(-)-ephedrine,CCG-204592,PSEUDOEPHEDRINE [MART.],(1S,2S) pseudoephedrine,7CUC9DDI9F,Sal-Phedrine,DivK1c_000451,Eciphin,HSDB 3177,Ephedrine [USAN:BAN],GTPL556,(S,S)-(+)-Pseudoephedrine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Pseudoephedrine Ephedrine,l-2-Methylamino-1-phenylpropanol, Ephedral,1-alpha-(1-Methylaminoethyl)benzyl alcohol,GTPL7286,BIDD:GT0817,SR-01000075166,SBI-0051498.P003, Drixoral Nasal Decongestant,BRD-K84175871-003-02-2,PSEUDOEPHEDRINE [HSDB],A820118,DB01364,(1R,2S)-2-(methylamino)-1-phenyl-1-propanol,Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaS)-,(1R,2S)-2-methylamino-1-phenylpropan-1-ol,Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-, Zephrol,l-Ephedrine,PSEUDOEPHEDRINE [INN], (1S,2S)-2-Methylamino-1-phenyl-1-propanol, (1S,2S)-(+)-Pseudoephedrine,(1R,2S)-1-phenyl-1-hydroxy-2-methylaminopropane,PDSP1_001347,Pseudoephedrine (INN),Ephedsol,(1R,2S)-2-(Methylamino)-1-phenylpropan-1-ol,L-(+)-Pseudoephedrine,Ephedrine,EPHEDRINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]


Estimated data

Solubilidad: -0.515 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 89.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.